top of page

Top Findings from FDA Inspections of Life Science Companies

Updated: Feb 15


FDA inspections are a critical component of ensuring the safety and efficacy of products in the life science industry. These inspections aim to identify and address any deficiencies or violations in the manufacturing, testing, and distribution of products. In this article, we will discuss the most common findings in FDA inspections for life science companies.

FDA inspections are a critical component of ensuring the safety and efficacy of products in the life science industry. These inspections aim to identify and address any deficiencies or violations in the manufacturing, testing, and distribution of products. In this article, we will discuss the most common findings in FDA inspections for life science companies.


Documentation and Recordkeeping Issues

One of the most common findings in FDA inspections is documentation and recordkeeping issues. These issues can include incomplete or inaccurate records, failure to maintain documents or data, and failure to follow established procedures for documentation.


Quality Control Problems

Quality control problems are another common finding in FDA inspections. These can include inadequate testing, failure to follow established quality control procedures, and incomplete or inadequate investigations into product defects or complaints.


Facility and Equipment Issues

FDA inspections frequently identify facility and equipment issues, such as inadequate cleaning and sanitation, inadequate maintenance, and lack of proper calibration or qualification of equipment.


Personnel Training and Qualification Issues

Personnel training and qualification issues are also common findings in FDA inspections. These issues can include inadequate training or documentation of training, lack of proper qualifications, and failure to follow established procedures.


Adverse Event Reporting Issues

Adverse event reporting issues are another common finding in FDA inspections. These can include inadequate or incomplete reporting, failure to follow established procedures for reporting, and failure to properly investigate and evaluate adverse events.



Labeling and Advertising Issues

FDA inspections may also identify labeling and advertising issues, such as inadequate or inaccurate labeling, failure to follow established labeling requirements, and inappropriate or misleading advertising.


In conclusion, FDA inspections can identify a range of deficiencies and violations in the manufacturing, testing, and distribution of life science products. The most common findings include documentation and recordkeeping issues, quality control problems, facility and equipment issues, personnel training and qualification issues, adverse event reporting issues, and labeling and advertising issues. By addressing these findings, life science companies can demonstrate their commitment to quality and compliance and maintain a positive relationship with the FDA.


Contact  BioBoston Consulting today or visit our  website to learn more about how we can support your organization.


20 views0 comments

Comments

Rated 0 out of 5 stars.
No ratings yet

Add a rating

Subscribe to Our Newsletter

Thanks for submitting!

bottom of page